Navigation Links
Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
Date:6/7/2008

ination with statins has been submitted to the U.S. Food and Drug Administration (FDA). Abbott and AstraZeneca are working together to co-develop and market a fixed-dose combination of TriLipix and CRESTOR, for which the companies plan to submit an NDA to the FDA in 2009.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
2. Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
3. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
4. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
5. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
6. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
7. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
8. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
9. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
10. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
11. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... WILSONVILLE, Ore. , Aug. 29, 2014 /PRNewswire-iReach/ ... its Accessory (Axilla) Strap for the SAM Junctional ... SAM Medical Products announced ... a voluntary recall to address a potential issue ... strap used for the Axilla application of the ...
(Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, ... President and Chief Executive Officer, will provide an update ... Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... August 29, 2014 According ... Market by Extraction type (SFE, Cold Pressed, Organic ... Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - Global ... defines and segments the Amaranth Seed Oil Market ... size in terms of value. The Amaranth Seed ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
(Date:9/1/2014)... -- Watching action shows on TV may be bad for ... more snack food while watching action films and programs than ... "We find that if you,re watching an action movie while ... Aner Tal, of the Cornell Food and Brand Lab, said ... distracting the program is, the more you will eat." ...
(Date:9/1/2014)... 01, 2014 More than 200 Lipitor ... a federal litigation that continues to progress in the ... LLP reports. , A federal Case List published ... the widely-used cholesterol medication by plaintiffs who developed Type ... claims, Pfizer Inc. failed to adequately warn patients and ...
(Date:9/1/2014)... Spain Monday 1 September 2014: Daily fruit consumption ... to 40%, according to research presented at ESC Congress ... findings from the seven year follow-up study of nearly ... that the more fruit people ate, the more their ... including ischaemic heart disease (IHD) and stroke, is the ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for blood-brain ... is expected to reach $38.7 million in 2014. This ... 2019, which is equivalent to 64.9% compound annual growth ... (RMT) segment is forecasted to grow at a CAGR ...
(Date:9/1/2014)... Secaucus, NJ (PRWEB) September 01, 2014 Registration ... For The Warriors® 5K and 1-Mile Race to be held ... at The Plaza Court Yard at Harmon Meadow in Secaucus, ... For The Warriors®, a national nonprofit dedicated to restoring a ... for our service members and our military families. , General ...
Breaking Medicine News(10 mins):Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2
... shared responsibility to a whole new level. Six ... $2 trillion in healthcare costs over the next decade. ... within our grasp.Blue Shield of California has long advocated ... are pleased that these groups are embracing the challenge ...
... 11, 2009 Iron chelating drugs have been heavily ... a form of blood cancer often treated with blood ... the body, are highly expensive and potentially toxic. A ... finds that their increased use has been propagated ...
... 11 Stephen J. Ubl, president and CEO of ... statement regarding today,s White House announcement of an industry ... are very pleased to join with President Obama and ... improving access to affordable, quality health care. As ...
... -- Jiangbo,Pharmaceuticals, Inc. (OTC Bulletin Board: GNPH) (the "Company"), ... People,s Republic,of China, today announced that its stock will ... the new ticker symbol "JGBO" as of May 12, ... symbol "GNPH" at the,end of May 11, 2009. , ...
... BlueCross BlueShield Give 40 in District Opportunity to Help Community Prevent HIV/AIDS ... ... and Education ( SHIRE ), Inc., is reaching out to 40 young ... help prevent the spread of HIV and AIDS and childhood obesity. ...
... Medical TechnologyWASHINGTON, May 11 Patients from across the ... about how medical technology has helped improve or save ... House of Representatives Energy & Commerce Committee hearing on ... repeal the Food and Drug Administration,s (FDA) preemption authority. ...
Cached Medicine News:Health News:AdvaMed Pleased to Work with the White House to Advance Health Reform 2Health News:Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP 2Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 2Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 3Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 4Health News:Patients Call for Continued FDA Preemption Authority 2Health News:Patients Call for Continued FDA Preemption Authority 3Health News:Patients Call for Continued FDA Preemption Authority 4
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
... Timesh 1.6 Titanium Cranial Fixation Systems ... benefits specifically requested by surgeons and ... cranioplasty implants may be either shaped ... procedure warrants, a pre-measured, cut, bent ...
... LeibingerTitanium Microplus System is a ... skeletal fixation armamentarium. It may ... vault, nasal, zygomatic and orbital ... especially where increased strength over ...
... Codman Sofwire Cable ... bony fixation including sublaminar ... maxillo facial surgery, sternotomy ... cables and a complete ...
Medicine Products: